FDA accepts Biogen BLA for rFVIIIFc in hemophilia A
This article was originally published in Scrip
Executive Summary
Biogen Idec on 13 May revealed the US FDA had accepted for review the company's biologic license application (BLA) for its recombinant factor VIII Fc fusion protein (rFVIIIFc) as a treatment for hemophilia A.